Healthcare / Medical DevicesNasdaqGM
$92.05
+1.39 (+1.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $16.5M · quality 58.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
50.3x
↑EV/EBITDA
41.4x
↑ROE
23.8%
↑Gross Margin
76.7%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.3%
FCF CAGR
+26.5%
FCF margin
19.7%
FCF / Net income
0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $83.8M · net income $22.5M · FCF $16.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $83.8M | $83.8M | $73.2M | $65.6M | $53.3M |
| Net Income | $22.5M | $22.5M | $19.2M | $17.2M | $12.8M |
| EBITDA | $27.3M | $27.3M | $22.8M | $20.8M | $16.3M |
| EPS | 1.75 | 1.75 | 1.50 | 1.35 | 1.02 |
| Gross Margin | 76.7% | 76.7% | 76.9% | 76.5% | 77.4% |
| Operating Margin | 31.2% | 31.2% | 30.0% | 30.6% | 29.3% |
| Net Margin | 26.8% | 26.8% | 26.3% | 26.2% | 24.1% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | 0.03 | 0.03 |
| Current Ratio | 7.13 | 7.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $16.5M | $16.5M | $16.8M | $5.5M | $8.2M |
| Returns | |||||
| ROE | 23.8% | 23.8% | 22.2% | 24.1% | 17.4% |
| Valuation | |||||
| P/E | 50.30 | 50.30 | 37.01 | 33.11 | 29.36 |
| EV/EBITDA | 41.45 | 41.45 | 28.86 | 25.05 | 19.80 |
| P/B | 12.51 | 12.51 | 8.17 | 7.96 | 5.14 |
| Growth & Yield | |||||
| Revenue Growth | 14.4% | 14.4% | 11.7% | 23.0% | — |
| EPS Growth | 16.7% | 16.7% | 11.1% | 32.4% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
67.1%
EPS terminal req.
$8.17
Spread vs growth
-50.5%
5Y implied EPS CAGR
41.4%
EPS terminal req.
$9.88
Spread vs growth
-24.7%
10Y implied EPS CAGR
24.7%
EPS terminal req.
$15.92
Spread vs growth
-8.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+59.9%
Start / end P/E
38.6x → 52.6x
EPS bridge
1.50 → 1.75
Residual
+6.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.